Brought to you by 
Neon Therapeutics and Apexigen enter melanoma trial collaboration
16 Nov 2021
Executive Summary
Neon Therapeutics Inc. and Apexigen Inc. signed a clinical trial collaboration to evaluate the combination of Neon’s neoantigen vaccine NEOPV01 with Apexigen’s antibody APX005M in a Phase Ib trial for metastatic melanoma.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Neon Therapeutics and Apexigen enter melanoma trial collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice